Can-Fite BioPharma Updates Liver Cancer Phase 3 Study
Ticker: CANF · Form: 6-K · Filed: Jun 5, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-update, drug-development, oncology
TL;DR
Can-Fite BioPharma's liver cancer drug trial is moving forward, check for updates.
AI Summary
On June 5, 2024, Can-Fite BioPharma Ltd. issued a press release providing an update on its pivotal Phase 3 study for its advanced liver cancer drug. The company is continuing to progress with its clinical trials.
Why It Matters
This update signals continued progress in Can-Fite's clinical development for a liver cancer treatment, which could impact future treatment options and the company's market position.
Risk Assessment
Risk Level: medium — Clinical trial updates for drug development companies carry inherent risks related to trial success, regulatory approval, and market adoption.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant and subject of the press release
- June 5, 2024 (date) — Date of the press release and filing
FAQ
What is the specific update regarding Can-Fite BioPharma's liver cancer pivotal Phase 3 study?
The press release issued on June 5, 2024, provides an update on the study, indicating continued progress.
What is the form type filed by Can-Fite BioPharma Ltd. on June 5, 2024?
Can-Fite BioPharma Ltd. filed a Form 6-K.
What is the primary focus of the press release mentioned in the filing?
The press release is titled 'Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study.'
What is the Commission File Number for Can-Fite BioPharma Ltd.?
The Commission File Number is 001-36203.
Does Can-Fite BioPharma Ltd. file annual reports under Form 20-F or Form 40-F?
Can-Fite BioPharma Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 189 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-06-05 07:03:54
Filing Documents
- ea020725001-6k_canfite.htm (6-K) — 8KB
- ea020725001ex99-1_canfite.htm (EX-99.1) — 11KB
- 0001213900-24-049861.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 5, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer